CDH1 and cancer: IHC examination with anti-E-cadherin and anti-vimentin antibodies further showed that cancer sites in metastatic lesions contain low E-cadherin/high vimentin levels, while conversely, normal tissue sites present with high E-cadherin/low vimentin expression levels.